Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear factor NF-kappa-B p105 subunit (NFKB1) is a pivotal transcription factor that plays a central role in regulating immune responses, inflammatory processes, cell survival, and proliferation. It is synthesized as a large precursor protein, p105, which undergoes proteasome-mediated processing to generate the active p50 subunit. The p50 subunit forms homodimers or heterodimers (most commonly with RelA/p65) to bind specific DNA sequences and regulate gene expression. Under normal physiological conditions, NFKB1 is sequestered in the cytoplasm in an inactive state by inhibitory IκB proteins. Upon stimulation by cytokines, pathogens, or stress, IκB is phosphorylated and degraded, allowing NFKB1 to translocate to the nucleus. Dysregulation of NFKB1 signaling is strongly implicated in chronic inflammatory diseases, autoimmune disorders, and various cancers, where constitutive activation promotes tumor cell survival, metastasis, and resistance to apoptosis. Consequently, NFKB1 and the broader NF-kappaB pathway represent highly attractive therapeutic targets. Pharmacological modulation is achieved through proteasome inhibitors like bortezomib, which prevent IκB degradation, as well as IKK inhibitors and anti-inflammatory agents. However, because NFKB1 is essential for normal host defense and tissue homeostasis, systemic and complete inhibition poses significant safety challenges, including severe immunosuppression and impaired wound healing.
Drugs targeting the NF-kappaB pathway primarily act by inhibiting the proteasomal degradation of IκBα (preventing NF-kappaB activation and nuclear translocation), inhibiting IκB kinase (IKK) phosphorylation, or directly blocking the nuclear translocation and DNA-binding activity of the NF-kappaB complex.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear factor NF-kappa-B p105 subunit (NFKB1) (NFKB1).